These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23726597)

  • 1. Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Mazanowska O; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Szyber P; Patrzałek D; Klinger M
    Transplant Proc; 2013 May; 45(4):1462-5. PubMed ID: 23726597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Krajewska M; Mazanowska O; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Dawiskiba T; Chudoba P; Klinger M
    Transpl Immunol; 2014 Jan; 30(1):24-9. PubMed ID: 24184747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity in hand transplantation: anti-HLA and non-HLA response.
    Banasik M; Jabłecki J; Boratyńska M; Kamińska D; Kościelska-Kasprzak K; Bartoszek D; Chełmoński A; Hałoń A; Baran W; Klinger M
    Hum Immunol; 2014 Aug; 75(8):859-62. PubMed ID: 24952209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Mazanowska O; Krajewska M; Zabińska M; Bartoszek D; Myszka M; Nowakowska B; Dawiskiba T; Lepiesza A; Chudoba P; Klinger M
    Transplant Proc; 2013 May; 45(4):1449-52. PubMed ID: 23726594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
    Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion.
    Solgi G; Pourmand G; Mehrsai A; Taherimahmoudi M; Nicknam MH; Ebrahimi Rad MR; Seraji A; Asadpoor A; Ansaripor B; Nikbin B; Amirzargar A
    Iran J Immunol; 2010 Mar; 7(1):18-29. PubMed ID: 20371916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
    Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
    Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
    Cardarelli F; Pascual M; Tolkoff-Rubin N; Delmonico FL; Wong W; Schoenfeld DA; Zhang H; Cosimi AB; Saidman SL
    Transpl Int; 2005 May; 18(5):532-40. PubMed ID: 15819801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of anti-human leukocyte antigen, anti-major histocompatibility complex class 1 chain-related antigen a, and anti-glutathione transferase-T1 antibodies on the long-term survival of renal allograft.
    Akgul SU; Oğuz FS; Çalışkan Y; Kekik C; Çağatay P; Türkmen A; Nane I; Aydın F; Temurhan S
    Transplant Proc; 2013 Apr; 45(3):890-4. PubMed ID: 23622580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
    Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
    Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance.
    Dragun D; Catar R; Philippe A
    Curr Opin Organ Transplant; 2013 Aug; 18(4):430-5. PubMed ID: 23838648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
    Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
    Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.